Xun Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10886053/publications.pdf

Version: 2024-02-01

44	5,405	147566	243296
papers	citations	31 h-index	44 g-index

46	46	46	6266
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sprouting Angiogenesis in Human Pituitary Adenomas. Frontiers in Oncology, 2022, 12, .	1.3	4
2	High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors. Frontiers in Oncology, 2022, 12, .	1.3	3
3	Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications. Neuroendocrinology, 2020, 110, 477-488.	1.2	23
4	Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2271-e2281.	1.8	19
5	Multiple Endocrine Neoplasia Type 1 (MEN1) Phenocopy Due to a Cell Cycle Division 73 (CDC73) Variant. Journal of the Endocrine Society, 2020, 4, bvaa142.	0.1	5
6	Meg3-DMR, not the Meg3 gene, regulates imprinting of the Dlk1-Dio3 locus. Developmental Biology, 2019, 455, 10-18.	0.9	8
7	Two Synchronous Pituitary Adenomas Causing Cushing Disease and Acromegaly. AACE Clinical Case Reports, 2019, 5, e276-e281.	0.4	1
8	DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma. Cancer Letters, 2019, 459, 135-144.	3.2	17
9	Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity. Cell Death and Disease, 2017, 8, e2746-e2746.	2.7	93
10	Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death. Autophagy, 2017, 13, 1404-1419.	4.3	78
11	Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3692-3703.	1.8	40
12	Stemness-related markers in cancer. Cancer Translational Medicine, 2017, 3, 87.	0.2	153
13	Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells. Oncotarget, 2016, 7, 58516-58530.	0.8	84
14	Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line. Molecular and Cellular Endocrinology, 2015, 416, 27-35.	1.6	59
15	Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Molecular and Cellular Endocrinology, 2014, 386, 16-33.	1.6	80
16	The Molecular Pathogenesis of Pituitary Adenomas: An Update. Endocrinology and Metabolism, 2013, 28, 245.	1.3	62
17	MEG3 noncoding RNA: a tumor suppressor. Journal of Molecular Endocrinology, 2012, 48, R45-R53.	1.1	643
18	Silencing of the Imprinted DLK1-MEG3 Locus in Human Clinically Nonfunctioning Pituitary Adenomas. American Journal of Pathology, 2011, 179, 2120-2130.	1.9	82

#	Article	IF	Citations
19	Activation of paternally expressed genes and perinatal death caused by deletion of theGtl2gene. Development (Cambridge), 2010, 137, 2643-2652.	1.2	127
20	Maternally Expressed Gene 3, an Imprinted Noncoding RNA Gene, Is Associated with Meningioma Pathogenesis and Progression. Cancer Research, 2010, 70, 2350-2358.	0.4	302
21	Maternally Expressed Gene 3 (MEG3) Noncoding Ribonucleic Acid: Isoform Structure, Expression, and Functions. Endocrinology, 2010, 151, 939-947.	1.4	296
22	Increased Expression of Angiogenic Genes in the Brains of Mouse Meg3-Null Embryos. Endocrinology, 2010, 151, 2443-2452.	1.4	148
23	Isolation and characterization of novel pituitary tumor related genes: A cDNA representational difference approach. Molecular and Cellular Endocrinology, 2010, 326, 40-47.	1.6	21
24	Hypoglycemia from IGF2 Overexpression Associated with Activation of Fetal Promoters and Loss of Imprinting in a Metastatic Hemangiopericytoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2226-2231.	1.8	24
25	Selective Loss of MEG3 Expression and Intergenic Differentially Methylated Region Hypermethylation in the MEG3/DLK1 Locus in Human Clinically Nonfunctioning Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4119-4125.	1.8	126
26	Regulation of growth hormone expression by Delta-like protein 1 (Dlk1). Molecular and Cellular Endocrinology, 2007, 271, 55-63.	1.6	35
27	Activation of p53 by MEG3 Non-coding RNA. Journal of Biological Chemistry, 2007, 282, 24731-24742.	1.6	570
28	Cyclic AMP stimulates MEG3 gene expression in cells through a cAMP-response element (CRE) in the MEG3 proximal promoter region. International Journal of Biochemistry and Cell Biology, 2006, 38, 1808-1820.	1.2	71
29	The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4482-4488.	1.8	187
30	Hypermethylation of the Promoter Region Is Associated with the Loss ofMEG3Gene Expression in Human Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2179-2186.	1.8	195
31	Receptor Internalization-Independent Activation of Smad2 in Activin Signaling. Molecular Endocrinology, 2004, 18, 1818-1826.	3.7	27
32	DNA Damage-induced Inhibition of Securin Expression Is Mediated by p53. Journal of Biological Chemistry, 2003, 278, 462-470.	1.6	78
33	A Pituitary-Derived MEG3 Isoform Functions as a Growth Suppressor in Tumor Cells. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5119-5126.	1.8	412
34	Overexpression of Wild-Type Activin Receptor Alk4-1 Restores Activin Antiproliferative Effects in Human Pituitary Tumor Cells. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4741-4746.	1.8	26
35	Loss of Expression ofGADD45Î³, a Growth Inhibitory Gene, in Human Pituitary Adenomas: Implications for Tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1262-1267.	1.8	141
36	Somatostatin Receptor-Specific Analogs: Effects on Cell Proliferation and Growth Hormone Secretion in Human Somatotroph Tumors1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2976-2981.	1.8	73

#	Article	IF	Citations
37	Activin Effects on Neoplastic Proliferation of Human Pituitary Tumors¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1009-1015.	1.8	46
38	Truncated Activin Type I Receptor Alk4 Isoforms Are Dominant Negative Receptors Inhibiting Activin Signaling. Molecular Endocrinology, 2000, 14, 2066-2075.	3.7	48
39	A Human Pituitary Tumor-Derived Folliculostellate Cell Line¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1180-1187.	1.8	37
40	Expression of Prolactin-Releasing Peptide and Its Receptor Messenger Ribonucleic Acid in Normal Human Pituitary and Pituitary Adenomas¹. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4652-4655.	1.8	26
41	Structure, Expression, and Function of Human Pituitary Tumor-Transforming Gene (PTTG). Molecular Endocrinology, 1999, 13, 156-166.	3.7	281
42	Pituitary Tumor Transforming Gene (PTTG) Expression in Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 761-767.	1.8	371
43	A Nuclear Receptor Corepressor Modulates Transcriptional Activity of Antagonist-Occupied Steroid Hormone Receptor. Molecular Endocrinology, 1998, 12, 513-524.	3.7	157
44	Ligand-dependent Cross-talk between Steroid and Thyroid Hormone Receptors. Journal of Biological Chemistry, 1996, 271, 14825-14833.	1.6	38